If it ain’t broke, break it: facilitating antigen cross-presentation

Rodríguez-Silvestre, Pablo; Kozik, Patrycja

doi:10.1016/j.molmed.2022.02.007

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported, delivered antigens are mainly processed by the proteasome in the cytosol and presented on major histocompatibility complex (MHC)‐I to generate the same epitopes as those in natural conditions. [ 40 ] We, therefore, speculated that DADNs might facilitate the escape of OVA and S proteins from the endo‐lysosomal system into the cytosol to enhance cross‐presentation. Furthermore, the MFI of co‐stimulatory molecules CD86 on BMDCs elevated significantly after treatment with SNPs or ONPs compared to the PBS group (Figure 3D).…”

Section: Resultsmentioning

confidence: 99%

Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications

Chen,

Zhang,

Yang

et al. 2023

Small

View full text Add to dashboard Cite

As one of the most common complications, infection causes the majority of mortality in cancer patients. However, therapeutic strategies that can simultaneously suppress tumors and protect patients from infection have been rarely reported. Here, the use of dual‐antigen‐displaying nanovaccines (DADNs) is described to elicit synergistic immunoactivation for treating cancer and preventing infectious complications. DADNs are prepared by wrapping immunoadjuvant‐loaded nanoparticles with a hybrid coating, which is fused from cell membranes that are separately genetically engineered to express tumor and infectious pathogenic antigens. Due to the presence of a dual‐antigen combination, DADNs are able to promote the maturation of dendritic cells and more importantly to trigger cross‐presentation of both combined antigens. During in vivo investigations, we find that DADNs can reverse immunosuppression by stimulating tumor‐associated antigen‐specific T‐cell responses, resulting in significantly delayed tumor growth in mice. These nanovaccines also elicit effective protective immunity against tumor challenges and induce robust production of pathogenic antigen‐specific immunoglobulin G antibody in a prophylactic study. This work offers a unique approach to develop dual‐mode vaccines, which are promising for synchronously treating cancer and preventing infection.

show abstract

Section: Resultsmentioning

confidence: 99%